Concepedia

Samuel E. DePrimo

SE

34

Publications

6.6K

Citations

28

H-Index

1996

Active since

Affiliations

Pfizer (United States)(Current)

Janssen (United States)

Dana-Farber Cancer Institute

Memorial Sloan Kettering Cancer Center

Stanford University

Samuel E. DePrimo is an author at Pfizer (United States) specializing in medicine, cell biology, and gene expression.

Top concepts

Publications per year

1996–2023

34

Publications

34

Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma

Robert J. Motzer, M. Dror Michaelson, Bruce G. Redman et al. · Journal of Clinical Oncology · 2005 · 1.6K citations · Full text

Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer

Sandrine Faivre, Catherine Delbaldo, Karina Vera et al. · Journal of Clinical Oncology · 2005 · 1.1K citations · Full text

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

Harold J. Burstein, Anthony Elias, Hope S. Rugo et al. · Journal of Clinical Oncology · 2008 · 483 citations · Full text

Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma

Brian I. Rini, M. Dror Michaelson, Jonathan E. Rosenberg et al. · Journal of Clinical Oncology · 2008 · 392 citations · Full text

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure

Suzanne George, Jean‐Yves Blay, Paolo G. Casali et al. · European Journal of Cancer · 2009 · 365 citations

, , +9

Rows per page

1–5 of 34